Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Financing Activities
Financing cash flows not reported separately.
Citius Oncology, Inc.NASDAQ: CTOR
Other Financing Activities · Q2 FY2026 · quarter ended Mar 2026
Other financing activities outflow grows to $0
Q2 FY2026 other financing activities was $0, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $0.
Context
- Other financing activities increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other financing activities holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | -100.0% |
| FY2024 | 2024-09-30 | 1.07M | -35.5% |
| FY2023 | 2023-09-30 | 1.66M | +533.7% |
| FY2022 | 2022-09-30 | (383.84K) | — |
Other Financing Activities vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's LTM Mar 2026 other financing activities of $0 is the 8th largest of the 10 companies compared; the peer median is $184K.
- Its year-over-year change of -100.0% is the 8th highest of 9, against a peer median of -26.3%.
- Other financing activities amounts to 0.0% of revenue for CTOR, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.03M | -1786.7% | — | 62.1% | |
| LTM Mar 2026 | $5.49M | +8.4% | — | 86.9% | |
| LTM Mar 2026 | $3M | +26.4% | — | 2.8% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $655.32K | -61.0% | — | — |
| LTM Mar 2026 | $319K | +82.3% | — | 0.6% | |
| LTM Mar 2026 | $184K | -92.4% | — | — | |
| LTM Mar 2026 | $41K | -96.4% | — | — | |
CTORCitius Oncology, Inc. | LTM Mar 2026 | $0 | -100.0% | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding CTOR) | $184K | -26.3% | — | 1.7% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|
| Net Income | 380.81K | 2.42M | (21.15M) | (24.76M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 576K | 1.06M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 64.24K | 411.77K | 13.2M | 9.89M |
| Accounts Receivables | 25.99K | 349.05K | 0 | 0 |
| Inventory | 0 | 0 | (2.13M) | (12.65M) |
| Accounts Payables | 0 | 0 | 2.42M | 9.52M |
| Other Working Capital | 38.25K | 62.72K | 12.91M | 13.02M |
| Other Non-Cash Items | (493.02K) | (3.43M) | 7.5M | 8.32M |
| Operating Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
| Capital Expenditures | 0 | 4 | (4) | (4) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (67.32M) | (1.32M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (5M) | (5.75M) |
| Investing Cash Flow | (67.32M) | (1.32M) | (5M) | (5.75M) |
| Debt Repayment | 0 | 0 | 3.8M | 0 |
| Common Stock Issued | 68.04M | 0 | 0 | 15.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (383.84K) | 1.66M | 1.07M | 0 |
| Financing Cash Flow | 67.66M | 1.66M | 4.87M | 15.17M |
| Effect of Forex Changes | 0 | 0 | (32.75K) | 0 |
| Net Change in Cash | 289.18K | (256.43K) | (32.63K) | 3.92M |
| Free Cash Flow | (47.97K) | (601.3K) | 126.35K | (5.49M) |
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.